Synlogic earns $2.5M milestone payment from Roche for IBD program

SYNLOGIC, INC.

Third milestone achieved under June 2021 Roche collaboration for Synthetic Biotic in IBD.
$2.5 million payment triggered; previous milestones in Sep 2021 and Aug 2022.
Roche retains exclusive option to license and commercialize the candidate.
Synlogic's Synthetic Biotics are oral, gut-restricted biotherapeutics for serious diseases.
Mylene Perreault, VP Research, emphasizes compelling fit with IBD disease biology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.